As the frustration with changes in healthcare grows, and after speaking with the vociferous advocates who are part of the ACR, you have decided that you need to become involved in advocacy for your patients, your practice and your profession. Welcome to the fold. How to Help from Home Many people indicate they aren’t more…
ACR Addresses Workforce Challenges at the State Level
Like many states in recent years, Georgia has struggled to provide patients with adequate access to rheumatologists and other cognitive specialists, with Georgia averaging 74,713 people per rheumatologist. Of equal concern, 31% of Georgia’s rheumatologists are approaching retirement age. During the current legislative session, the ACR has stepped up with a proposal to alleviate some…
Democrats Support Expanding Medicare, with Some Caveats that Could Matter to Voters
WASHINGTON/ST. GEORGE, S.C.—After launching his 2020 presidential bid last week, John Hickenlooper took a different stance on establishing a “Medicare-for-all” government health insurance program than many of his Democratic competitors. “I probably would oppose Medicare-for-all just because there are over 150 million people, Americans who have some form of private insurance through their business, and…
Practices Now Contributing to RheumPAC
Last year the ACR’s nonpartisan political action committee, RheumPAC, raised nearly $150,000 from individual contributors. Starting in 2019, the addition of the RheumPAC Advocacy Fund, where rheumatology practices and state societies can contribute corporate dollars, is expected to support RheumPAC fundraising efforts in an effort to surpass this dollar amount, giving rheumatology an even stronger…
Why Fellows Should Care about Advocacy
As a physician, I am an advocate. I am an advocate for my patients individually and collectively, and I am an advocate for my field: pediatric rheumatology. My own experiences as a patient drive me to integrate my patients’ perspectives into my medical decision making, and although my academic training has prepared me to best…
U.S. House Democrats Introduce Sweeping Medicare for All Bill
WASHINGTON (Reuters)—Democrats in the U.S. House of Representatives unveiled an ambitious proposal to move all Americans into the government’s Medicare health insurance program, tapping into public frustration over the rising cost of healthcare that has become a key issue for the party as it seeks to gain control of Congress and the White House in…
Early Activity Holds Signs of Hope for 2019 State Legislative Cycle
The 2019–2020 legislative cycle in the states holds real hope and opportunity for critical reforms to protect rheumatology practices and patients. It is important to note that because of the state legislative process, bill passage almost always comes later in the legislative session. Although the rheumatology community has not yet seen many official wins, early…
Arthritis Advocacy Spotlights the Military: Veterans, including a rheumatologist, educate lawmakers about arthritis’ impact & the need for research funding
On Feb. 13, the ACR co-sponsored Arthritis 101, its biennial arthritis advocacy lunch briefing at the U.S. Capitol, highlighting the disproportionate impact of rheumatic disease on active members of the armed forces and veterans. The event, co-sponsored by the Arthritis Foundation (AF), is part of the ACR’s effort to support inclusion of $20 million in…
Advocacy in Action: How the ACR Is Working for You
Out of the turmoil of 2018 came a number of significant victories for the rheumatology field, all of which are thanks to the ACR’s volunteers, who spearheaded communication with policymakers. We are thrilled to share these successes and look forward to working with you in an even more productive 2019 (view this larger on our…
Eli Lilly Backs U.S. Proposal on Drug Rebates to Lower Costs
(Reuters)—Eli Lilly and Co. on Wednesday embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen, saying it could lower the cost of insulin and other prescription drugs for patients. Lilly, along with other major insulin makers, Sanofi SA and Novo Nordisk, has been under mounting pressure from…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 94
- Next Page »